- Conditions
- Communication
- Interventions
- Communication skills training, Communication skills training-Facilitator
- Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 196,555
matching trials from the live ClinicalTrials.gov search.
- Conditions
- End-Stage Renal Disease
- Interventions
- exposure to a high-calcium dialysate bath
- Procedure
- Lead sponsor
- James B. Wetmore, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Lithium Carbonate, Prophylactic cranial irradiation
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Follicle Development, Ovarian Follicle, Follicle Count, Follicle Size, Oral Contraceptive
- Interventions
- Desogestrel/ethinyl estradiol and ethinyl estradiol, 28-day drospirenone oral contraceptive, 28-day levonorgestrel oral contraceptive
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 206 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- Does the Vagus Nerve Mediate the Effects of Xenin-25
- Interventions
- Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Advanced Melanoma
- Interventions
- Botensilimab, Balstilimab
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Fullerton, California • Santa Monica, California + 4 more
- Conditions
- Postpartum Depression
- Interventions
- Placebo, SAGE-547 60 μg/kg/h, SAGE-547 90 μg/kg/h
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 27 more
- Conditions
- Peanut Allergy
- Interventions
- AR101
- Biological
- Lead sponsor
- Aimmune Therapeutics, Inc.
- Industry
- Eligibility
- 1 Year to 55 Years
- Enrollment
- 911 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 53 more
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Technetium Tc 99M Mebrofenin
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Obesity, Severe, Pediatric Obesity
- Interventions
- Meal-replacement Therapy
- Dietary Supplement
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Obesity
- Interventions
- Standard, Early Intervention
- Behavioral
- Lead sponsor
- The Miriam Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Chronic Periodontitis
- Interventions
- Scaling and root planing, Scaling and root planing with solution
- Procedure
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Suramin Drug:Docetaxel Drug: Carboplatin, Placebo Drug: Docetaxel Drug: Carboplatin
- Drug
- Lead sponsor
- Optimum Therapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Richmond, Virginia
- Conditions
- Glioblastoma Multiforme
- Interventions
- TPI 287, Bevacizumab
- Drug
- Lead sponsor
- Cortice Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 8 more
- Conditions
- Ductal Carcinoma in Situ
- Interventions
- lapatinib
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Colorectal Cancer, Appendiceal Cancer, Peritoneal Carcinoma
- Interventions
- Oxaliplatin, mFOLFIRI
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Achalasia
- Interventions
- Per-oral Endoscopic Esophagomyotomy (POEM)
- Procedure
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Fetal Growth Restriction, Preeclampsia Severe
- Interventions
- Expanded panel cell free DNA testing (non-invasive prenatal testing), Placental biopsy, Umbilical cord blood
- Genetic
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 70 participants
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Cystic Fibrosis
- Interventions
- GLPG2222 50 mg, GLPG2222 100 mg, Placebo, GLPG2222 200 mg, GLPG2222 400 mg
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 7
- States / cities
- Chatom, Alabama • Little Rock, Arkansas • Orlando, Florida + 4 more
- Conditions
- Melanoma
- Interventions
- recMAGE-A3 + AS15 ASCI
- Biological
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Pregnant Women With Singleton Pregnancies
- Interventions
- Food Kit
- Other
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- College Station, Texas • Dallas, Texas • Mansfield, Texas
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- MRI Screening Form, MRI, Demographic / Medical Data form, MRI Screening Form, MRI. Demographic / Medical Data
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
- Interventions
- vorinostat, cisplatin, radiation therapy, Correlative Studies
- Drug · Radiation · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Contraception, Hypogonadism
- Interventions
- Oral Testosterone, Leuprolide (Lupron), Dutasteride
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington